Carboplatin AUC

Phase 2Small molecule

Carboplatin AUC is one of 4 small molecule programs targeting Metastatic Non-squamous Non Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Non-Squamous Non Small Cell Lung CancerRecruiting

Metastatic Non-Squamous Non Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Metastatic Non-Squamous Non Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Taxotere

AAvyxa

Phase 2

2 3

Visugromab

CCatalYm GmbH

Phase 2

2 4

Carboplatin AUC

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Metastatic Non-Squamous Non Small Cell Lung Cancer

NCT07098988

Clinical

Trials by Indication[1]

Gastroesophageal Junction1 trial

Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)

Terminated·—·Phase 1/2·NCT01395537·13 enrolled

Non-Small Cell Lung Cancer1 trial

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT03916419·26 enrolled

Breast Cancer1 trial

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Terminated· GSK logo

GSK·Phase 2·NCT01220128·66 enrolled

Carboplatin1 trial

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

Completed·NNYU Langone Health·Phase 2·NCT02744898·23 enrolled

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07098988·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Carboplatin AUC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin AUC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin AUC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Carboplatin AUC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Gastroesophageal Junction1 trial

Non-Small Cell Lung Cancer1 trial

Breast Cancer1 trial

Carboplatin1 trial

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News